Background: Tacrolimus is the most frequently used immunosuppressive drug for preventing
renal rejection. However, its use is hampered by its narrow therapeutic index and large intra …

Aims The aims of this study were to describe the pharmacokinetics of tacrolimus immediately
after kidney transplantation, and to develop a clinical tool for selecting the best starting dose …

Objectives: The aims of this study were to develop a population pharmacokinetic model of
tacrolimus in adult kidney transplant recipients, to use this model to compare cytochrome …

Background Tacrolimus has a narrow therapeutic range and requires dose adjustment,
usually based on the trough blood concentration but preferably on the area under the …

Background A prospective validation of pharmacokinetic population (Pk pop) of Tacrolimus
(Tac) for dose adjustment in kidney transplant patients was assessed in only one study. The …

Aims The aim was to develop a theory‐based population pharmacokinetic model of
tacrolimus in adult kidney transplant recipients and to externally evaluate this model and two …

Introduction: Following organ transplantation there is a risk of the body rejecting the
transplanted organ. To prevent this solid organ transplant recipients (SOTRs) are dependent …

Abstract Background and Objectives Advagraf® is a new extended-release once-daily
formulation of tacrolimus, a potent immunosuppressant widely used in renal transplantation …

Purpose To identify patient characteristics that influence tacrolimus individual dose
requirement in kidney transplant recipients. Methods Data on forty-four 12-h …

Purpose Numerous studies have been conducted on the population pharmacokinetics of
tacrolimus in adult renal transplant recipients. It has been reported that the cytochrome P450 …